Lead Product(s) : KRP-M223
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
KYORIN and Novartis Enter into a Global License Agreement for KRP-M223
Details : Under this agreement, KYORIN grants Novartis an exclusive worldwide license to develop, manufacture, and commercialize KRP-M223, an MRGPRX2 antagonist for allergic and inflammatory diseases.
Product Name : KRP-M223
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 03, 2025
Lead Product(s) : KRP-M223
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Asahi Kasei Pharma
Deal Size : $163.5 million
Deal Type : Licensing Agreement
Asahi Kasei Signs Anti-CX3CR1 Antibody License Agreement for Global Reach
Details : Under the licensing agreement, Asahi Kasei Pharma has acquired worldwide exclusive rights to develop and commercialize PFKR an anti-CX3CR1 antibody from Chiome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Asahi Kasei Pharma
Deal Size : $163.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Foundation for Biomedical Research and Innovation at Kobe
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A novel anti-PD-1 agonist monoclonal antibody, which inhibits the function of PD-1 (anti-PD-1 blocking antibodies) leading in enhanced anti-tumor immunity.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Foundation for Biomedical Research and Innovation at Kobe
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Sana Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Fujifilm and Sana Biotechnology Enter Cell Therapy Partnership
Details : FUJIFILM Cellular Dynamics grants Sana a non-exclusive license under intellectual property rights owned or controlled by FUJIFILM Cellular Dynamics, and will provide iPSC cell lines (including research-grade and/or Good Manufacturing Practices (GMP)-grad...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Sana Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement